"Daunorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
| Descriptor ID |
D003630
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200 D04.615.562.050.200 D09.408.051.059.200
|
| Concept/Terms |
Daunorubicin- Daunorubicin
- Daunomycin
- Rubomycin
- Dauno-Rubidomycine
- Dauno Rubidomycine
- Rubidomycin
|
Below are MeSH descriptors whose meaning is more general than "Daunorubicin".
Below are MeSH descriptors whose meaning is more specific than "Daunorubicin".
This graph shows the total number of publications written about "Daunorubicin" by people in this website by year, and whether "Daunorubicin" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Daunorubicin" by people in Profiles.
-
Transplant outcomes after CPX-351 vs 7?+?3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv. 2022 09 13; 6(17):4989-4993.
-
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul; 8(7):e481-e491.
-
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv. 2021 03 23; 5(6):1719-1728.
-
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018 09 10; 36(26):2684-2692.
-
Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. Cancer Chemother Pharmacol. 2014 Oct; 74(4):831-8.
-
Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 01; 68(9):3161-8.